Table 1.
General Characteristics of Patients Who Received Chimeric Antigen Receptor T-Cell Therapy
| Variable | No. (%) |
|---|---|
| No. | 152 |
| Sex (female) | 85 (55.9) |
| Age, y, median (IQR) | 55 (38–65) |
| Hematologic malignancy | |
| Non-Hodgkin lymphoma | 61 (40.1) |
| ALL | 59 (38.8) |
| Multiple myeloma | 34 (22.4) |
| HSCT | 92 (60.5) |
| Comorbidities | |
| Hypertension | 25 (16.4) |
| Previous solid tumor | 23 (15.1) |
| Chronic heart disease | 22 (14.5) |
| Diabetes mellitus | 9 (5.9) |
| Chronic pulmonary disease | 7 (4.6) |
| Chronic liver disease | 6 (3.9) |
| Chronic kidney disease | 5 (3.3) |
| Solid organ transplant | 1 (0.7) |
| CAR T-cell therapy | |
| Academic-ARI001 | 121 (79.6) |
| Axicabtagene ciloleucel | 27 (17.8) |
| Lisocabtagene maraleucel | 2 (1.3) |
| Tisagenlecleucel | 2 (1.3) |
| Days between timepoints, median (IQR) | |
| Admission and infusion | 1 (1–6) |
| Infusion and tocilizumab | 6 (5–9) |
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: ALL, acute lymphoblastic leukemia; CAR, chimeric antigen receptor; HSCT, hematopoietic stem cell transplant; IQR, interquartile range.